With over a decade of experience in oncology drug discovery and development, Dr. Tessie Ng brings strategic scientific leadership across the entire preclinical development spectrum. She has successfully advanced programs from discovery through development candidate selection and into the IND-enabling and first-in-human clinical stages, leading teams to execute on preclinical strategies spanning pharmacology and toxicology as well as translational that integrate PD and biomarker plans for early clinical development. She also has expertise in authoring nonclinical regulatory documents for IND. Her therapeutic modality experience includes biologics (monospecific and multispecific antibodies) as well as small molecules. Most recently, she has led the development of a bispecific antibody from the discovery stage through to a Phase 1 study in advanced solid tumors.

Prior to joining Kivu Bioscience, she held roles at Bristol Myers Squibb, Harpoon Therapeutics, and Amgen. Dr. Ng obtained her Ph.D. in Molecular and Cellular Biology from the University of Washington / Fred Hutch Cancer Center, followed by post-doctoral training at Stanford University.